Rossmax InternationalROCO:4121 +0.75%58 EBITDA Margin % is 7.87% as of Dec. 2025, which is 8% below its 10-year median of 8.53. GuruFocus rates ROCO:4121 with a GF Score™ of 58/100 and a GF Value™ of NT$19.07 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Rossmax International ranks better than 51.47% on this metric.
Rossmax International (ROCO:4121) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rossmax International EBITDA Margin % Related Terms
Rossmax International EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Rossmax International's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4121 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Rossmax International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossmax International EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rossmax International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rossmax International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rossmax International (ROCO:4121) has a EBITDA Margin % of 7.87% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rossmax International and its competitors. This is near median its historical median of 8.53. Over the past decade, Rossmax International's EBITDA Margin % has ranged from 2.24 to 13.35. According to the industry distribution chart, Rossmax International ranks #396 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 48.5%.
Is Rossmax International's EBITDA Margin % too high?
Rossmax International's current EBITDA Margin % of 7.87% is near median its 10-year median of 8.53. Over the past 10 years, this metric has ranged from a low of 2.24 to a high of 13.35. The Medical Devices & Instruments industry median EBITDA Margin % is 7.39. Rossmax International's value of 7.87% is 6.6% above this industry median. Based on the distribution chart, Rossmax International ranks #396 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Rossmax International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossmax International's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Rossmax International ranks #396 out of 816 companies for EBITDA Margin %. This puts Rossmax International in the upper half of its industry. The industry median EBITDA Margin % is 7.39. Rossmax International's value of 7.87% is 6.6% above this benchmark. Historically, Rossmax International's own EBITDA Margin % has ranged from 2.24 to 13.35 over the past decade. While the company's 10-year median is 8.53 vs. the industry median of 7.39, Rossmax International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rossmax International's current EBITDA Margin % of 7.87% is 6.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rossmax International and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossmax International's current EBITDA Margin % is 7.87%, which is near median its own 10-year median of 8.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossmax International stock overvalued right now?
Based on GuruFocus' analysis, Rossmax International (ROCO:4121) is currently considered Possible Value Trap. The stock's GF Value™ is NT$19.07, compared to a current price of NT$13.40 — trading 29.7% below its estimated fair value. The current EBITDA Margin % is 7.87%, which is near median its 10-year median of 8.53 and 6.6% above the Medical Devices & Instruments industry median of 7.39. Rossmax International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rossmax International (ROCO:4121), the current EBITDA Margin % is 7.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossmax International (ROCO:4121) Overvalued in 2026?
Based on GuruFocus' analysis, Rossmax International stock appears to be undervalued.
The current stock price of NT$13.40 is trading 29.7% below its estimated GF Value™ of NT$19.07.
GuruFocus considers Rossmax International to be Possible Value Trap.
Key valuation signals for ROCO:4121:
EBITDA Margin %: 7.87% (near median its 10-year median of 8.53)
GF Value™: NT$19.07 vs. price of NT$13.40 (29.7% below fair value)
Industry Position: 6.6% above the Medical Devices & Instruments median (#396 of 816)
No single metric tells the full story. See the ROCO:4121 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossmax International Ltd is mainly engaged in medical equipment manufacturing, wholesale or retail, and the medicine and cosmetics channels. The group has three reportable departments: the medical device department, the retail channel department, and the investment department. The medical device department manufactures various types of medical supplies. The retail channel department is engaged in the retail of cosmetics, medical equipment, food products, and beverages. Geographically, it derives key revenue from the Taiwan region and the rest from Iraq, Algeria, the U.S.A, the U.A.E, Malaysia, Iran, Kazakhstan, South Korea, Norway, Croatia, Tunisia, and Other.
58GF Score
Get the complete analysis for ROCO:4121
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4121 has been successfully added to your 
